[ad_1] HONG KONG, Feb. 12, 2025 /PRNewswire/ — Akeso, Inc. (9926. HK) (“Akeso” or the “Company”) announced the recent completion of the first patient enrollment in the Phase 3 randomized, double-blind, multicenter clinical trial (COMPASSION-30/AK104-309) for […]
Tag: Akeso
Akeso Announces the Completion of Patient Enrollment in the Phase III Clinical Trial (HARMONi-6) Comparing Ivonescimab and Tislelizumab for First-Line Treatment of Sq-NSCLC
[ad_1] HONG KONG, Feb. 5, 2025 /PRNewswire/ — Akeso, Inc. (9926.HK) (“Akeso” or the “Company”) is excited to announce the completion of patient enrollment in the global Phase III clinical trial (HARMONi-6/AK112-306) evaluating ivonescimab, its independently […]
Akeso’s Cadonilimab (PD-1/CTLA-4 Bispecific Antibody) Combination Therapy for PD-(L)1 Resistant NSCLC Showcased in Oral Presentation at 2024 Asian Conference on Lung Cancer
[ad_1] HONG KONG, Dec. 4, 2024 /PRNewswire/ — Akeso, Inc. (9926.HK) (“Akeso” or the “Company”) announced the results from a prospective, open-label, single-arm, multi-center phase Ib/II clinical study (AK104-IIT-018) of cadonilimab (PD-1/CTLA-4 bispecific antibody) in […]
Akeso Announced the Inclusion in China’s National Reimbursement Drug List of Cadonilimab and Ivonescimab
[ad_1] HONG KONG, Nov. 27, 2024 /PRNewswire/ — Akeso, Inc. (9926. HK) (“Akeso” or the “Company”) is pleased to announce that two of its independently developed, globally pioneering bispecific antibody drugs—cadonilimab Injection (PD-1/CTLA-4 bispecific antibody) […]
Akeso’s Penpulimab Combination Therapy for First-line Treatment of Hepatocellular Carcinoma Accepted by NMPA
[ad_1] HONG KONG, Nov. 22, 2024 /PRNewswire/ — Akeso, Inc. (9926.HK) (“Akeso” or the “Company”) announced that the National Medical Products Administration (NMPA) of China has accepted its supplemental new drug application (sNDA) for penpulimab, a […]
